Vertex Pharmaceuticals Incorporated (VRTX)
NASDAQ: VRTX · Real-Time Price · USD
408.18
+2.91 (0.72%)
At close: Dec 24, 2024, 1:00 PM
407.90
-0.28 (-0.07%)
After-hours: Dec 24, 2024, 2:14 PM EST
Vertex Pharmaceuticals Stock Forecast
Stock Price Forecast
The 25 analysts with 12-month price forecasts for VRTX stock have an average target of 507.72, with a low estimate of 408 and a high estimate of 586. The average target predicts an increase of 24.39% from the current stock price of 408.18.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for VRTX stock from 30 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Jul '24 | Aug '24 | Sep '24 | Oct '24 | Nov '24 | Dec '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 8 | 9 | 9 | 10 | 11 | 12 |
| Buy | 10 | 9 | 9 | 8 | 8 | 8 |
| Hold | 6 | 7 | 7 | 9 | 9 | 9 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 1 | 1 | 1 | 1 | 1 | 1 |
| Total | 25 | 26 | 26 | 28 | 29 | 30 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Truist Securities | Truist Securities | Strong Buy Maintains $550 → $460 | Strong Buy | Maintains | $550 → $460 | +12.70% | Dec 23, 2024 |
| Scotiabank | Scotiabank | Hold Maintains $426 → $430 | Hold | Maintains | $426 → $430 | +5.35% | Dec 23, 2024 |
| JP Morgan | JP Morgan | Buy Maintains $503 → $500 | Buy | Maintains | $503 → $500 | +22.49% | Dec 23, 2024 |
| Barclays | Barclays | Hold Maintains $509 → $418 | Hold | Maintains | $509 → $418 | +2.41% | Dec 20, 2024 |
| BMO Capital | BMO Capital | Buy Maintains $566 → $520 | Buy | Maintains | $566 → $520 | +27.39% | Dec 20, 2024 |
Financial Forecast
Revenue This Year
11.11B
from 9.87B
Increased by 12.54%
Revenue Next Year
12.05B
from 11.11B
Increased by 8.52%
EPS This Year
0.60
from 13.89
Decreased by -95.71%
EPS Next Year
19.19
from 0.60
Increased by 3,121.81%
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 11.5B | 14.4B | 16.3B | |||
| Avg | 11.1B | 12.1B | 13.2B | |||
| Low | 10.6B | 11.0B | 11.6B |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 16.8% | 29.8% | 35.2% | |||
| Avg | 12.5% | 8.5% | 9.8% | |||
| Low | 7.3% | -0.5% | -3.4% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 2.13 | 23.10 | 28.03 | |||
| Avg | 0.60 | 19.19 | 20.84 | |||
| Low | 0.05 | 15.95 | 16.73 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | -84.7% | 3,777.9% | 46.1% | |||
| Avg | -95.7% | 3,121.8% | 8.6% | |||
| Low | -99.6% | 2,578.4% | -12.8% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.